Antifungal therapy – Page 13

Disseminated sporotrichosis caused by Sporothrix brasiliensis with testicular involvement

mycolabadmin

This case report describes a rare fungal infection caused by Sporothrix brasiliensis in a 35-year-old man living with HIV/AIDS. The infection spread throughout his body, affecting his skin, lungs, brain, and testicles. Doctors initially thought the testicular involvement was cancer and removed the testicle, but lab tests confirmed it was a fungal infection. The patient was successfully treated with antifungal medications and remains disease-free one year later.

Low Antigen Titre Disseminated Cryptococcosis in Immunocompromised Hosts: Two Challenging Case Reports

mycolabadmin

Two patients with weakened immune systems developed serious fungal blood infections from Cryptococcus despite having unusually low levels of fungal markers in their blood. One was a kidney transplant patient and the other had HIV. Neither showed signs of brain infection, which is unusual for this disease. Both were successfully treated with aggressive antifungal medications once blood cultures confirmed the disseminated infection.

Formulation, characterization, and in vitro antifungal evaluation of liposomal terbinafine prepared by the ethanol injection method

mycolabadmin

Researchers developed a new way to deliver the antifungal drug terbinafine using tiny fat-based particles called liposomes. These particles are designed to carry the drug more effectively to infected tissues while reducing harmful side effects. The optimized formulation showed promise for treating stubborn fungal infections, especially those affecting the brain, with significantly reduced toxicity compared to the drug alone.

Clinical Mycology Today: Emerging Challenges and Opportunities

mycolabadmin

Fungal infections are becoming more common due to new cancer treatments and other medical advances, while some fungal species are developing resistance to standard antifungal medications. The good news is that several new antifungal drugs are in development with better safety profiles and novel mechanisms to fight these infections. However, the field faces challenges including limited specialized mycologists and difficulty designing clinical trials to properly test new treatments.

Candidemia due to Candida lambica in a neutropenic oncology patient: A rare case report

mycolabadmin

A 56-year-old cancer patient developed a serious bloodstream infection caused by a rare yeast called Candida lambica despite taking antifungal medications. Doctors identified the infection using genetic sequencing and found that the organism was sensitive to a different antifungal drug called voriconazole. After switching medications and removing the patient’s central line, the infection cleared up. This case demonstrates the importance of accurately identifying fungal infections and testing which medications work best against them.

Clinical Challenges and Predictive Risk Factors for Outcomes in COVID-19–Associated Mucormycosis

mycolabadmin

During the COVID-19 pandemic, a dangerous fungal infection called mucormycosis has become a serious complication, especially for patients with uncontrolled diabetes or those taking certain medications. Researchers studied 180 patients with this condition and found that the infection can spread from the sinuses to the eyes and brain, leading to severe outcomes. The most important factors in surviving this infection are early detection, keeping blood sugar controlled, careful use of steroids, and aggressive treatment with antifungal medications and sometimes surgery.

Epidermophyton floccosum, an etiological agent of tinea pedis and tinea unguium: about two cases

mycolabadmin

Two elderly patients with toenail and foot fungal infections caused by Epidermophyton floccosum were diagnosed using modern molecular testing methods. Traditional microscopic examination alone was difficult, but real-time PCR provided accurate identification. Both patients were treated with terbinafine, a common antifungal medication. The study highlights how modern DNA testing improves diagnosis compared to older methods.

Disseminated cryptococcosis in an HIV patient with hepatitis C as the associated risk factor

mycolabadmin

A 29-year-old patient with HIV and hepatitis C developed a serious fungal infection caused by Cryptococcus neoformans that spread to the brain. The infection was diagnosed through blood and spinal fluid tests and treated successfully with antifungal medications. This case shows why it is important to recognize and treat fungal infections quickly in people with weakened immune systems and multiple health conditions.

The expression of fungal CotH, human glucose-regulated protein 78 (GRP78), and predicted miRNAs in macrophages and diabetic mice infected with Rhizopus oryzae

mycolabadmin

Mucormycosis is a serious fungal infection caused by Rhizopus oryzae that is particularly dangerous for people with diabetes. This study shows that a fungal protein called CotH3 attaches to a human cell receptor called GRP78, allowing the fungus to invade cells more easily in diabetic patients. The research found that diabetes increases GRP78 production, making fungal invasion more likely, while antifungal treatment (liposomal amphotericin B) can reduce the expression of both CotH3 and GRP78.

Case Commentary: Successful use of olorofim for the treatment of multi-drug-resistant Lomentospora prolificans infection in a child

mycolabadmin

A young girl contracted a dangerous drug-resistant fungal infection in her knee after an injury, which failed to respond to standard antifungal treatments. Doctors obtained special access to an experimental antifungal drug called olorofim through a compassionate use program. The child showed improvement within two weeks and was completely cured after six months of treatment with no signs of the infection returning two years later, making this the first successful case of this new drug being used in a child.

Research Topic: Antifungal therapy